ADDvise Group raises its EBITDA target for 2022

07-04-2022   Regulatory press release

In the light of the company’s continued progress, the Board of Directors of ADDvise Group have decided to raise the 2022 EBITDA target from the previous target communicated on 23 September 2021. For the financial year 2022, rolling 12 months pro forma basis, ADDvise expects to reach an EBITDA result of at least SEK 200 million before acquisition costs (adjusted EBITDA). The previous EBITDA target was at least SEK 150 million on a pro forma basis for 2022. The earlier communicated revenue target of SEK 1 billion in net sales on a pro forma basis before the end of 2022 remains unchanged.

ADDvise Group’s financial targets for 2022 are:

  • 2022 EBITDA pro forma rolling 12 months target SEK 200 million
  • 2022 net sales pro forma rolling 12 months target SEK 1 billion

“Our previous target of SEK 150 million in EBITDA will be reached pro forma in Q2. This, combined with the fact that we have good visibility of our acquisition pipeline means that we can increase our targets”. CEO Rikard Akhtarzand comments.

For further information, please contact:

CEO Rikard Akhtarzand
+46 765-25 90 71

rikard.akhtarzand@addvisegroup.se


Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 7 April 2022 at 16:40 CEST.
 

About ADDvise Group
 

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Latest press releases

Interim report 2025, January 1–June 30

Regulatory

In the second quarter of 2025, organic sales adjusted for currency effects increased, driven by steady demand for laboratory equipment and rental of equipment for clinical studies. Operating cash flow improved in the quarter, and EBITA was in line with last year with a stronger margin. Through the new capital structure, ADDvise’s annual interest expenses…

Invitation to presentation of interim report April 1 – June 30, 2025

Non-regulatory

ADDvise Group publishes its interim report April 1 – June 30, 2025 on Thursday, July 17, 2025 at 7.45 am (CET). Media, investors and analysts are invited to attend a webcast and teleconference on the same day at 14:00 (CET). CEO, Staffan Torstensson, and CFO, Johan Irwe, will present the report. Webcast If you wish to…

ADDvise announces that the conditions for early redemption of outstanding secured bonds have been fulfilled

Regulatory

ADDvise Group AB (publ) (“ADDvise” or the “Company”) announced on 14 May 2025 that ADDvise intends to redeem the Company’s outstanding senior secured bonds with ISIN SE0020180271 and ISIN NO0013180786 (the “Early Redemption”). The Early Redemption was conditional upon the entering into of the new secured facilities agreement of the equivalence of SEK 450 million…